Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives Average Rating of “Hold” from Analysts

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $2.5833.

VVOS has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Monday, April 20th. Ascendiant Capital Markets dropped their price target on Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, HC Wainwright dropped their price target on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research note on Friday, April 17th.

Vivos Therapeutics Price Performance

Vivos Therapeutics stock opened at $0.64 on Monday. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.24 and a current ratio of 0.24. The business’s 50-day simple moving average is $1.09 and its two-hundred day simple moving average is $1.68. The company has a market cap of $8.79 million, a PE ratio of -0.31 and a beta of 6.25. Vivos Therapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $7.95.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Wednesday, April 15th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.08). The firm had revenue of $3.82 million for the quarter, compared to analysts’ expectations of $7.10 million. Vivos Therapeutics had a negative net margin of 121.37% and a negative return on equity of 849.22%. During the same quarter in the previous year, the firm posted ($2.22) EPS. Equities analysts anticipate that Vivos Therapeutics will post -1.33 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the company’s stock in a transaction on Tuesday, March 31st. The shares were acquired at an average price of $1.34 per share, for a total transaction of $1,813,857.50. Following the purchase, the insider owned 1,353,625 shares in the company, valued at $1,813,857.50. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Vivos Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Sequoia Financial Advisors LLC acquired a new position in shares of Vivos Therapeutics in the 1st quarter valued at about $28,000. Acorn Wealth Advisors LLC acquired a new position in shares of Vivos Therapeutics in the 4th quarter valued at about $30,000. XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics in the 2nd quarter valued at about $65,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Vivos Therapeutics in the 2nd quarter valued at about $220,000. Finally, DRW Securities LLC lifted its holdings in shares of Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after buying an additional 74,441 shares during the period. Institutional investors and hedge funds own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.